Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 6/2011

01-06-2011 | Review

Breast cancer proteomics: a review for clinicians

Authors: E. R. C. G. N. Galvão, L. M. S. Martins, J. O. Ibiapina, H. M. Andrade, S. J. H. Monte

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2011

Login to get access

Abstract

Purpose

Breast cancer is one of the major health problems of the Western world. Although the survival rate has improved with progress in screening and adjuvant systemic therapies, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis, demonstrating the presence of micrometastasis. The underlying molecular mechanism of the disease needs to be better understood. Allied to genomics, proteomics technologies promise to be valuable for identifying new markers that improve screening, early diagnosis, prognosis and prediction of therapeutic response or toxicity, as well as the identification of new therapeutic targets. In this review, we present features of proteomic technology and its main implications, focusing on the protein profile in tumor tissues/cells through MALDI/SELDI, as well as on the current proteomic challenges in the breast cancer study.

Methods

We performed a research of protein profiling studies using mass spectrometry in breast cancer to identify potential biomarkers.

Results

Many protein peaks have been reported to bear significant diagnostic, prognostic or predictive value; however, the candidate biomarkers have not been validated for use in clinical patient care.

Conclusions

Proteomics is under development and, despite technical barriers that precede the use of proteomics analysis in clinical practice and breast cancer complexity, MALDI-TOF/SELDI-TOF MS proteomic platforms with their innovations are powerful analytical tools for the detection of better protein biomarkers, since the studies are conducted with adequate statistical power and analytical rigor. In the near future, they will be able to fulfill their role in personalized medicine.
Literature
Abramovitz M, Leyland-Jones B (2006) A systems approach to clinical oncology: focus on breast cancer. Proteome Sci 4:5PubMedCrossRef
Aggarwal K, Choe LH, Lee KH (2006) Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 5:112–120PubMedCrossRef
Andersson T, Johansson M, Bolmsjo G, James P (2007) Automating MALDI sample plate loading. J Proteome Res 6:894–896PubMedCrossRef
Barazi HO, Zhou L, Templeton NS, Krutzsch HC, Roberts DD (2002) Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res 62:1541–1548PubMed
Bergman AC, Benjamin T, Alaiya A et al (2000) Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21:679–686PubMedCrossRef
Bertucci F, Goncalves A (2008) Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncol 4:271–287PubMedCrossRef
Bertucci F, Birnbaum D, Goncalves A (2006) Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5:1772–1786PubMedCrossRef
Bouchal P, Roumeliotis T, Hrstka R, Nenutil R, Vojtesek B, Garbis SD (2009) Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 8:362–373PubMedCrossRef
Brozkova K, Budinska E, Bouchal P et al (2008) Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 10:R48PubMed
Callesen AK, Vach W, Jorgensen PE et al (2008) Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J Proteome Res 7:1395–1402PubMedCrossRef
Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103PubMedCrossRef
Cornett DS, Mobley JA, Dias EC et al (2006) A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics 5:1975–1983PubMedCrossRef
Cowherd SM, Espina VA, Petricoin EF III, Liotta LA (2004) Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer 5:385–392PubMedCrossRef
Dean RA, Overall CM (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 6:611–623PubMedCrossRef
Ferguson AT, Evron E, Umbricht CB et al (2000) High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97:6049–6054PubMedCrossRef
Fu H, Subramanian RR, Masters SC (2000) 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617–647PubMedCrossRef
Gast MC, Schellens JH, Beijnen JH (2009) Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116:17–29PubMedCrossRef
Gilabert M, Audebert S, Viens P, Borg JP, Bertucci F, Goncalves A (2010) Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers. Bull Cancer 97:321–339PubMed
Giometti CS, Tollaksen SL, Chubb C, Williams C, Huberman E (1995) Analysis of proteins from human breast epithelial cells using two-dimensional gel electrophoresis. Electrophoresis 16:1215–1224PubMedCrossRef
Goncalves A, Charafe-Jauffret E, Bertucci F et al (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420–1433PubMedCrossRef
Habermann JK, Roblick UJ, Luke BT et al (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131:1020–1029; quiz 284
Hondermarck H (2003) Breast cancer: when proteomics challenges biological complexity. Mol Cell Proteomics 2:281–291PubMed
Hondermarck H, Vercoutter-Edouart AS, Revillion F et al (2001) Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1:1216–1232PubMedCrossRef
Hondermarck H, Tastet C, Yazidi-Belkoura El et al (2008) Proteomics of brest cancer: the quest for markers and therapeutic targets. J Proteome Res 7:1403–1411PubMedCrossRef
Hudelist G, Singer CF, Pischinger KI et al (2006) Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 6:1989–2002PubMedCrossRef
Kabbage M, Chahed K, Hamrita B et al (2008) Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol 2008:564127PubMedCrossRef
Kamradt MC, Chen F, Cryns VL (2001) The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276:16059–16063PubMedCrossRef
Kamradt MC, Lu M, Werner ME et al (2005) The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280:11059–11066PubMedCrossRef
King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef
Leong S, Christopherson RI, Baxter RC (2007) Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol Biochem 20:579–590PubMedCrossRef
Li DQ, Wang L, Fei F, Hou YF et al (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6:3352–3368PubMedCrossRef
Liu Y, Liu H, Han B, Zhang JT (2006) Identification of 14-3-3sigma as contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66:3248–3255PubMedCrossRef
Martini PG, Delage-Mourroux R, Kraichely DM et al (2000) Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol Cell Biol 20:6224–6232PubMedCrossRef
Mian S, Ball G, Hombuckle J et al (2003) A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 3:1725–1737PubMedCrossRef
Miller I, Crawford J, Gianazza E (2006) Protein stains for proteomic applications: which, when, why? Proteomics 6:5385–5408PubMedCrossRef
Mitrunen K, Hirvonen A (2003) Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 544:9–41PubMedCrossRef
Moreira JM, Ohlsson G, Rank FE, Celis JE (2005) Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4:555–569PubMedCrossRef
Moyano JV, Evans JR, Chen F et al (2006) Alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116:261–270PubMedCrossRef
Nakagawa T, Huang SK, Martinez SR et al (2006) Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 66:11825–11830PubMedCrossRef
Nesvizhskii AI (2007) Protein identification by tandem mass spectrometry and sequence database searching. Methods Mol Biol 367:87–119PubMed
Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK (2003) Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA 100:9330–9335PubMedCrossRef
Page MJ, Amess B, Townsend RR et al (1999) Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 96:12589–12594PubMedCrossRef
Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167PubMedCrossRef
Patton WF (2002) Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 771:3–31PubMedCrossRef
Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26:1–10PubMedCrossRef
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
Pucci-Minafra I, Cancemi P, Marabeti MR et al (2007) Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts. Proteomics Clin Appl 1:118–129PubMedCrossRef
Reis-Filho JS, Lakhani SR (2003) The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 5:313–319PubMedCrossRef
Reis-Filho JS, Tutt NA (2008) Triple negative tumours: a critical review. Histopathology 52:108–118PubMedCrossRef
Ricolleau G, Charbonnel C, Lode L et al (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6:1963–1975PubMedCrossRef
Rodenhiser D, Mann M (2006) Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 174:341–348PubMed
Sanders ME, Dias EC, Xu BJ et al (2008) Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res 7:1500–1507PubMedCrossRef
Schulz DM, Bollner C, Thomas G et al (2009) Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 8:3430–3438PubMedCrossRef
Sethuraman M, Clavreul N, Huang H, McComb ME, Costello CE, Cohen RA (2007) Quantification of oxidative posttranslational modifications of cysteine thiols of p21ras associated with redox modulation of activity using isotope-coded affinity tags and mass spectrometry. Free Radic Biol Med 42:823–829PubMedCrossRef
Simpson RJ, Bernhard OK, Greening DW, Moritz RL (2008) Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol 12:72–77PubMedCrossRef
Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef
Stastny J, Prasad R, Fosslien E (1984) Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis. Clin Chem 30:1914–1918PubMed
Sutton CW, Rustogi N, Gurkan C et al (2010) Quantitative proteomic profiling of matched normal and tumor breast tissues. J Proteome Res 9:3891–3902PubMedCrossRef
Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, Sager R (1990) Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA 87:2319–2323PubMedCrossRef
Traub F, Feist H, Kreipe HH, Pich A (2005) SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol Res Pract 201:763–770PubMedCrossRef
Traub F, Jost M, Hess R et al (2006) Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest 86:246–253PubMedCrossRef
Tsitsilonis OE, Bekris E, Voutsas IF et al (1998) The prognostic value of alpha-thymosins in breast cancer. Anticancer Res 18:1501–1508PubMed
Umar A, Dalebout JC, Timmermans AM, Foekens JA, Luider TM (2005) Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics 5:2680–2688PubMedCrossRef
Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S (2001) Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20:3348–3353PubMedCrossRef
van’t Veer LJ, Dai H, van de Vijver MJ et al (2003) Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5:57–58CrossRef
Vercoutter-Edouart AS, Lemoine J, Le Bourhis X et al (2001) Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61:76–80PubMed
Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220:263–280PubMedCrossRef
Weiss JM, Goode EL, Ladiges WC, Ulrich CM (2005) Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 42:127–141PubMedCrossRef
Wilkins MR, Sanchez JC, Gooley AA et al (1996) Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13:19–50PubMed
Wirth PJ (1989) Specific polypeptide differences in normal versus malignant breast tissue by two-dimensional electrophoresis. Electrophoresis 10:543–554PubMedCrossRef
Worland PJ, Bronzert D, Dickson RB et al (1989) Secreted and cellular polypeptide patterns of MCF-7 human breast cancer cells following either estrogen stimulation or v-H-ras transfection. Cancer Res 49:51–57PubMed
Wright GL Jr (1974) Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann Clin Lab Sci 4:281–293PubMed
Wulfkuhle JD, McLean KC, Paweletz CP et al (2001) New approaches to proteomic analysis of breast cancer. Proteomics 1:1205–1215PubMedCrossRef
Yiu CC, Sasano H, Ono K, Chow LW (2010a) Changes in protein expressions after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance. Expert Opin Investig Drugs 19(Suppl 1):S79–S89
Yiu CC, Chanplakorn N, Chan MS et al (2010b) Down regulation of Heat Shock Protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor (AI) therapy in breast cancer patients. Anticancer Res 30:3465–3472PubMed
Zeidan BA, Cutress RI, Murray N et al (2009) Proteomic analysis of archival breast cancer serum. Cancer Genomics Proteomics 6:141–147PubMed
Zhang F, Chen JY (2010) Discovery of pathway biomarkers from coupled proteomics and systems biology methods. BMC Genomics 11(Suppl 2):512CrossRef
Zhang Z, Bast RC Jr, Yu Y et al (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882–5890PubMedCrossRef
Zhang Y, Newcomb PA, Egan KM et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358PubMedCrossRef
Metadata
Title
Breast cancer proteomics: a review for clinicians
Authors
E. R. C. G. N. Galvão
L. M. S. Martins
J. O. Ibiapina
H. M. Andrade
S. J. H. Monte
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-0978-0

Other articles of this Issue 6/2011

Journal of Cancer Research and Clinical Oncology 6/2011 Go to the issue

Original Paper

Association between age and synchronous liver metastasis in female colorectal cancer patients

Original Paper

Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus

Original Paper

The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis

Original Paper

Capecitabine-based chemotherapy for metastatic colorectal cancer

Original Paper

Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells

Original Paper

ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits